Suppr超能文献

金斯评分法优化了肝细胞癌的预后预测:一项新应用。

The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application.

作者信息

Pinato David J, Karamanakos Georgios, Ishizuka Mitsuru, Smirne Carlo, Pirisi Mario, Kubota Keiichi, Sharma Rohini

机构信息

Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.

Department of Gastroenterological Surgery, Dokkyo Medical University, Mibu, Tochigi, Japan.

出版信息

Liver Int. 2015 Nov;35(11):2458-65. doi: 10.1111/liv.12841. Epub 2015 May 11.

Abstract

BACKGROUND & AIMS: There are a number of prognostic scores in hepatocellular carcinoma (HCC), none of which is optimal in predicting overall survival (OS) in the individual patient, particularly in intermediate stage disease, where patients are not surgically treatable but may qualify for a wide range of palliative interventions. We evaluated the prognostic role of a biochemical algorithm, the Kings Score (KS), in the palliative setting of care.

METHODS

We used the algorithm [age x AST x INR]/platelet count to derive the KS. Full clinical data including Barcelona Clinic Liver Cancer (BCLC) stage were studied in a training set of 97 patients from the UK. Independent predictors of survival identified in multivariate analysis were validated in an independent cohort of 766 patients from Japan and Italy.

RESULTS

In both training and validation sets, KS was confirmed as an independent predictor of OS (P < 0.01). Ad-hoc subgroup analysis revealed the KS to be prognostic in the palliative setting, being able to subclassify patients presenting with intermediate and advanced disease according to BCLC criteria (P < 0.001).

CONCLUSION

The KS integrates into the BCLC system to improve prognostic substratification in the palliative setting of care. The KS may help reducing disease heterogeneity and refine treatment allocation in intermediate-advanced HCC.

摘要

背景与目的

肝细胞癌(HCC)有多种预后评分系统,但在预测个体患者的总生存期(OS)方面,没有一种是最佳的,特别是在中期疾病中,这类患者无法进行手术治疗,但可能适合多种姑息性干预措施。我们评估了一种生化算法——金斯评分(KS)在姑息治疗中的预后作用。

方法

我们使用[年龄×谷草转氨酶(AST)×国际标准化比值(INR)]/血小板计数的算法得出KS。在来自英国的97例患者的训练集中研究了包括巴塞罗那临床肝癌(BCLC)分期在内的完整临床数据。在多变量分析中确定的生存独立预测因素在来自日本和意大利的766例患者的独立队列中进行了验证。

结果

在训练集和验证集中,KS均被确认为OS的独立预测因素(P < 0.01)。专门的亚组分析显示KS在姑息治疗中具有预后价值,能够根据BCLC标准对中晚期疾病患者进行亚分类(P < 0.001)。

结论

KS纳入BCLC系统可改善姑息治疗中的预后分层。KS可能有助于减少疾病异质性并优化中晚期HCC的治疗分配。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验